Barr, Shire Settle Litigation Over Adderall

Law360, New York (November 1, 2003, 12:00 AM EST) -- Barr Laboratories Inc. and Shire Pharmaceuticals Group agreed to end litigation over attention deficit drug Adderall, the two companies said.

Shire sued Barr in 2002, charging that Barr's generic version of Shire's Adderall infringed on Shire's rights in the appearance of the product.

Adderall XR is a once daily extended-release, mixed salt amphetamine product that is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

In November 2002, Barr filed an ANDA for Adderall XR Capsules, 5 mg, 10 mg, 15 mg, 20 mg, 25...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.